{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:28:43Z","timestamp":1790252923947,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jhep.2017.02.012","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T16:30:54Z","timestamp":1487781054000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients \u2013 French ANRS CO13 HEPAVIH cohort"],"prefix":"10.1016","volume":"67","author":[{"given":"Lionel","family":"Piroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wittkop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Miailhes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Neau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zucman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Morlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Aumaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lascoux-Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Teicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouz\u00e9","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Esterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.02.012_b0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.012_b0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2013.04.005","article-title":"Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?","volume":"59","author":"Rockstroh","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.012_b0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV coinfection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0025","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","article-title":"Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000","volume":"28","author":"Morlat","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2017.02.012_b0030","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2017.02.012_b0035","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/cid\/cis779","article-title":"Response to pegylated interferon plus ribavirin among HIV\/hepatitis C virus-coinfected patients with compensated liver cirrhosis","volume":"55","author":"Mira","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0040","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-2005-142-1-A12","article-title":"Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections","volume":"142","author":"Torriani","year":"2005","journal-title":"ACP J Club"},{"key":"10.1016\/j.jhep.2017.02.012_b0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2015.10.010","article-title":"HCV viral load at baseline and at week 4 of telaprevir\/boceprevir based triple therapies are associated with virological outcome in HIV\/hepatitis C co-infected patients","volume":"73","author":"Salmon","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2017.02.012_b0050","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.02.012_b0055","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.02.012_b0060","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE COINFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jhep.2017.02.012_b0065","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"Sulkowski","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2017.02.012_b0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2017.02.012_b0075","doi-asserted-by":"crossref","unstructured":"Wyles D, Brau N, Kottilil S, Daar E, Workowski K, Luetkemeyer A, et al. Sofosbuvir\/velpatasvir for 12 weeks in patients coinfected with HCV and HIV-1: The ASTRAL-5 Study. In: The International Liver Congress \u2013 EASL \u2013 European Association for the Study of the Liver; 2016; Barcelona, Spain; 2016.","DOI":"10.1016\/S0168-8278(16)00129-X"},{"key":"10.1016\/j.jhep.2017.02.012_b0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.02.012_b0085","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world?","volume":"62","author":"Saeed","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0090","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciw119","article-title":"Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV","volume":"62","author":"Del Bello","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0095","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkw203","article-title":"High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV\/HCV-coinfected patients: a real-world perspective","volume":"71","author":"Hawkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2017.02.012_b0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral direct-acting antiviral regimens in HIV\/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort","volume":"63","author":"Sogni","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0105","unstructured":"Recommendations for testing, managing and treating hepatitis C \u2013 AASLD; 2016."},{"key":"10.1016\/j.jhep.2017.02.012_b0110","unstructured":"Recommendations AFEF sur la prise en charge des h\u00e9patites virales C \u2013 AFEF Societ\u00e9 Fran\u00e7aise d'H\u00e9patologie; 2016."},{"key":"10.1016\/j.jhep.2017.02.012_b0115","unstructured":"European AIDS Clinical Society EACS \u2013 Guidelines Version 8.0.; 2015."},{"key":"10.1016\/j.jhep.2017.02.012_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2334-10-303","article-title":"The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006\u20132010","volume":"10","author":"Loko","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0125","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/liv.12799","article-title":"Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV\/HCV genotype 1-coinfected patients","volume":"35","author":"Miailhes","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.02.012_b0130","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans affairs national health care system","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.012_b0135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.012_b0140","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.02.012_b0145","first-page":"1","article-title":"Current treatment options for hepatitis C patients co-infected with HIV","author":"Rockstroh","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.02.012_b0150","doi-asserted-by":"crossref","first-page":"e0141164","DOI":"10.1371\/journal.pone.0141164","article-title":"Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV\/HCV coinfected patients","volume":"10","author":"Poizot-Martin","year":"2015","journal-title":"PLoS One"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T15:55:37Z","timestamp":1658678137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817301071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0168827817301071"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.02.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients \u2013 French ANRS CO13 HEPAVIH cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}